Sulfasalazine
Catalog No.: GC16868Purity:>98.00%Synonyms: Azopyrin, NSC 203730, NSC 667219
Sulfasalazine is a sulfonamide drug.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 599-79-1
10mM (in 1mL DMSO)In Stock
$45.00
1
500mgIn Stock
$36.00
1
1gIn Stock
$45.00
1
5gIn Stock
$72.00
1
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $45.00 | In Stock | 1 | |
| 500mg | $36.00 | In Stock | 1 | |
| 1g | $45.00 | In Stock | 1 | |
| 5g | $72.00 | In Stock | 1 |
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com
Citations
1 publicationsPublications from researchers using this productDescription
Sulfasalazine is a sulfonamide drug [1]. Sulfasalazine can inhibit the NF-κB pathway and reduce cytokine release, thereby regulating immune responses [2]. Sulfasalazine is commonly used to treat inflammatory bowel disease and rheumatoid arthritis [3-4].
In Jurkat T-lymphocytes, Sulfasalazine (0.2mM, 0.5mM, 1mM, 2mM; 24h) induces cell apoptosis [5]. In endothelial cells, Sulfasalazine (0.125mM, 24h) inhibits tritiated thymidine incorporation and cell proliferation [6]. In RBL5 cells, Sulfasalazine (1.25mM, 24h) inhibits NF-κB/Rel activation in mouse T lymphocytes [7].
In ICR mice, Sulfasalazine (250mg/kg, 500mg/kg, 1000mg/kg; po; 4 weeks) significantly increased serum levels of ALT, ALP and TBIL [8]. In DSS-Induced ulcerative colitis mice, Sulfasalazine (30mg/kg, 60mg/kg; ip; 7d) can inhibit colon length and mucosal inflammatory infiltration [9]. In middle cerebral artery occlusion mice, Sulfasalazine (5mg/kg, 10mg/kg; iv; single injection) could reduce the infarct size and improve neuro-motor function [10].
References:
[1]. Goldman P, Peppercorn MA. Sulfasalazine. New England Journal of Medicine. 1975 Jul 3; 293(1): 20-23.
[2]. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. The Journal of clinical investigation. 1998 Mar 1; 101(5): 1163-1174.
[3]. Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Annals of Internal Medicine. 1984 Sep 1; 101(3): 377-386.
[4]. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs. 2005 Sep; 65: 1825-1849.
[5]. Liptay S, Fulda S, Schanbacher M, et al. Molecular mechanisms of sulfasalazine‐induced T‐cell apoptosis. British Journal of Pharmacology. 2002 Nov; 137(5): 608-620.
[6]. Sharon P, Drab EA, Linder JS, et al. The effect of sulfasalazine on bovine endothelial cell proliferation and cell cycle phase distribution: comparison with olsalazine, 5-aminosalicylic acid, and sulfapyridine. The Journal of laboratory and clinical medicine. 1992 Jan 1; 119(1): 99-107.
[7]. Liptay S, Bachem M, Hacker G, et al. Inhibition of nuclear factor kappa B and induction of apoptosis in T‐lymphocytes by sulfasalazine. British journal of pharmacology. 1999 Dec; 128(7): 1361-1369.
[8]. Li YC, Shen JD, Lu SF, et al. Transcriptomic analysis reveals the mechanism of sulfasalazine-induced liver injury in mice. Toxicology Letters. 2020 Mar 15; 321: 12-20.
[9]. Shin MR, Kim KJ, Kim SH, et al. Comparative Evaluation between Sulfasalazine Alone and in Combination with Herbal Medicine on DSS‐Induced Ulcerative Colitis Mice. BioMed Research International. 2017; 2017(1): 6742652.
[10]. Li X, Ding H, Jing J, et al. Sulfasalazine improves neuronal function in mice with ischemic stroke by inhibiting the STING/NF-κB pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 May; 398(5): 5797-5810.
Protocol
| Cell experiment [1]: | |
|
Cell lines |
Jurkat T-lymphocytes |
|
Preparation Method |
Jurkat T-lymphocytes were grown under standard conditions in RPMI 1640 medium supplemented with 100U/mL penicillin, 100μg/mL streptomycin, 2mM glutamine, and 10% FCS. Sulfasalazine was freshly dissolved in the medium and added to the culture at the indicated concentrations and times. |
|
Reaction Conditions |
0.2mM, 0.5mM, 1mM, 2mM; 24h |
|
Applications |
Sulfasalazine induces apoptosis in human Jurkat T-lymphocytes. |
| Animal experiment [2]: | |
|
Animal models |
ICR mice |
|
Preparation Method |
Forty ICR mice were randomly divided into four experimental groups (n = 10): control group and Sulfasalazine (SASP) groups (250mg/kg, 500mg/kg, 1000mg/kg). SASP (98% of purity) was dissolved in 0.1% dimethyl sulfoxide (DMSO) and were administered by oral gavage in a volume of 10mL/kg for 4 weeks. Control group received equal volume of 0.1% DMSO. |
|
Dosage form |
250mg/kg, 500mg/kg, 1000mg/kg; po; 4 weeks |
|
Applications |
Sulfasalazine significantly increased serum levels of ALT, ALP and TBIL. |
|
References: |
|
Product Documents
Purity:>98.00%Appearance:A solid
Chemical Properties
CAS No.
599-79-1
Synonyms
Azopyrin, NSC 203730, NSC 667219
Chemical Name
(3Z)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid
SMILES
C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)NN=C3C=CC(=O)C(=C3)C(=O)O
Molecular Formula
C18H14N4O5S
Molecular Weight
398.39
Solubility
≥ 17.7 mg/mL in DMSO
Storage
Store at RT
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
g/mol
Reviews
Review for Sulfasalazine
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%